The ALX3 Knockout HeLa Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal knockout population with targeted disruption of the ALX3 gene in HeLa cells. This heterogeneous pool of edited cells enables loss-of-function studies of ALX3, a paired-type homeobox transcription factor involved in craniofacial development and epithelial-mesenchymal transition (EMT). The polyclonal format avoids clonal artifacts and preserves genetic diversity for robust phenotypic analysis.
HeLa cells, derived from human cervical adenocarcinoma, are an HPV-18-positive epithelial line widely used in cancer and signaling research. Their epithelial origin and capacity to undergo EMT in response to exogenous stimuli make them an ideal host for examining transcription factors that regulate cell plasticity, migration, and adhesion.
ALX3 acts downstream of WNT (e.g., WNT3A, WNT5A via Frizzled receptors and ??-catenin), BMP (BMP4?CSMAD1/5/8), and FGF (FGF8?CFGFR) pathways. It forms complexes with PAX3 and MSX1 to transcriptionally regulate genes critical for EMT and morphogenesis. Key ALX3 targets include SNAI2 and TWIST1, which promote mesenchymal features, and CDH1/CDH2, whose cadherin switching alters cell adhesion. This network positions ALX3 as a node connecting morphogen signals to invasive behavior.
Disrupting ALX3 in HeLa cells provides a model to probe its role in maintaining epithelial versus mesenchymal states. Loss of ALX3 is expected to reduce expression of SNAI2 and TWIST1, potentially impairing cell migration and invasion. As ALX3 is implicated in frontonasal dysplasia and may contribute to tumorigenesis, this polyclonal knockout system enables dissection of its context-dependent functions in cancer cell plasticity and drug response.
Applications include western blotting and RT-qPCR for EMT markers (SNAI2, TWIST1, CDH1, CDH2), immunofluorescence for cadherin localization, and migration/invasion assays. The cells support drug sensitivity screening and studies of signaling crosstalk by treating with WNT3A or BMP4. For further information or ordering, please contact Ascent Research.
